TITLE:
Global Cardiovascular Risk of the HIV Positive Patients Receiving Antiretroviral Therapy in Brazzaville
AUTHORS:
Stéphane Méo Ikama, Franck Ekoba-Otende, Jospin Makani, Amélia Bokilo, Bienvenu Ossibi-Ibara, Louis Igor Ondze-Kafata, Bertrand Fikhaem Ellenga-Mbolla, Thierry Raoul Gombet, Suzy Gisèle Kimbally-Kaky
KEYWORDS:
HIV Infection, Antiretroviral Therapy, Metabolic Disorders, Global Cardiovascular Risk, Congo
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.9 No.8,
August
19,
2019
ABSTRACT: A cross-sectional, descriptive and analytical study was conducted from January to August 2015 at the Brazzaville Ambulatory Treatment Center and atthe National Blood Transfusion Center. The objective was to contribute to improvingthe care of people living with HIV under antiretroviral therapy by assessing their global cardiovascular risk (CVR). The variables studied focused on the epidemiological, clinical and biological aspects. The global CVR was assessedby the Framingham and WHO/ISH scores. There were 135 HIV-positive subjects,including 64 treated patients and 71 untreated HIV+ subjects. The subjects were divided into 83 men (61.5%) and 52 women (38.5%), with an average age of 42.6 ± 2.9 old years. The subjects were single people (62.2%), of a secondary educational level (63.7%), and civil servants (32.6%). The main risk factors found were dyslipidaemia (60%), obesity (36%), smoking (12.6%), hypertension (5.9%), diabetes (0.7%). The metabolic syndrome was found in seven cases (11.3%). The global CVR according to the score of Framingham, initially moderated at 17.2%, and mean at 1.5% within treated patients, was mean at 9.4% and high at 1.6% of the subjects respectively at the sixth month of treatment (p CVR under antiretroviral therapy. Preventive actions are highly recommended.